Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 21, 2009

Roche to Use Kinaxo’s Technology to Hunt for Biomarkers Related to Antibodies in Development

  • Roche Diagnostics will use Kinaxo Biotechnologies’ phosphoproteomics technology, PhosphoScout®, to find biomarkers related to antibody-based therapeutics currently under development at Roche. The technology has been developed as a quantitative phosphoproteomic service, which the company says allows the dissection of cellular signal transduction pathways and their response to drug treatment. The platform is based on mass spectrometry methods, enabling the analysis of 15,000 phosphorylation sites in a single experiment. 

    The agreement follows just a week after Kinaxo announced a deal with Bayer Vital, under which PhosphoScout® will be used to identify novel biomarkers associated with drug response in a clinical trial evaluating Nexavar® in acute myeloid leukaemia patients.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »